# Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

> **NCT01522443** · PHASE3 · TERMINATED · sponsor: **Exelixis** · enrollment: 119 (actual)

## Conditions studied

- Prostate Cancer
- Castration Resistant Prostate Cancer
- Pain
- Prostatic Neoplasms

## Interventions

- **DRUG:** cabozantinib
- **DRUG:** mitoxantrone
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT01522443
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2014-10
- **Final completion:** 2015-01-13
- **Target enrollment:** 119 (ACTUAL)
- **Why stopped:** Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522443, "Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01522443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*